Online inquiry

IVTScrip™ pSP6-VEE-mRNA-Anti-TNFRSF17, 2857916 Vector   (CAT#: GTVCR-WQ17MR)

This product GTVCR-WQ17MR is an effective transcription system suitable for a variety of research, including the in vitro translation, self-amplifying mRNA studies and protein expression. The system was driven by the SP6 promoter to efficiently generate mRNA ecoding antibody which targeting TNFRSF17. The vector contains the self-replicating Venezuelan equine encephalitis (VEE) virus RNA replicon, which resulting the mRNA expression at a high level.

SPECIFIC INQUIRY

3' poly(A):
Inquiry
Specifications
Product type Vector
Promoter SP6
Resistance Ampicillin
Species Humanized
RefSeq NM_001192.3
Applications IVT; Self-amplifying mRNA (SAM) research; Gene therapy research
Format Solution
Concentration 1 µg/µl
Quantity 10 µg
Target Gene
Gene ID 608
UniProt ID Q02223
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ pSP6-VEE-mRNA-Anti-TNFRSF17, 2857916 Vector (GTVCR-WQ17MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTVCR-WQ965MR IVTScrip™ pSP6-VEE-mRNA-Anti-CEACAM5, CEA-IL-2v Vector Vector CEA-IL-2v
GTVCR-WQ1531MR IVTScrip™ pT7-VEE-mRNA-Anti-EGFR, IMGN-289 Vector Vector IMGN-289
GTVCR-WQ13MR IVTScrip™ pSP6-VEE-mRNA-Anti-S, 2130 Vector Vector 2130
GTVCR-WQ2195MR IVTScrip™ pT7-VEE-mRNA-Anti-APP, PF-04360365 Vector Vector PF-04360365
GTVCR-WQ581MR IVTScrip™ pSP6-VEE-mRNA-Anti-HGF, AV-299 Vector Vector AV-299
GTVCR-WQ1160MR IVTScrip™ pSP6-VEE-mRNA-Anti-Alkaline phosphatase substitute, ENB-0040 Vector Vector ENB-0040
GTVCR-WQ1074MR IVTScrip™ pT7-VEE-mRNA-Anti-Factor IX substitute, CSL654 Vector Vector CSL654
GTVCR-WQ2319MR IVTScrip™ pT7-VEE-mRNA-Anti-CD3E&MS4A1, REGN-1979 Vector Vector REGN-1979
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW